The Pilot and Feasibility Program is a special feature of the O'Brien Urology Research Center application that allows sponsored institutions to fund important new pilot projects with promising potential, but would have difficulty in providing sufficient preliminary data for an independently funded NIH grant. This is a crucial part of our Center as it provides a pipeline and testing ground for novel substrates for translational impact. These projects are intended to last one year with the possibility of a second year of support with the demonstration of sufficient progress and are budgeted with the intention of that the majority of the funds be spent on supplies, rather than salary support. To be eligible, the applicant must have a current academic appointment at any of the Johns Hopkins Medical Institutions, Howard University or University of Maryland. Applicants must hold an M.D., or Ph.D. degree or both. The applicants are expected to provide evidence of a significant research commitment (at least 15% effort commitment) to ensure that the proposal can in fact be addressed in an effective and productive way. A minimum of two developmental research projects will be funded annually partially by funds supported through the O'Brien Center mechanism but more substantially through an Institutional cost-sharing effort by which we are committing at least $200,000 per year to further support these projects.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Specialized Center (P50)
Project #
1P50DK082998-01A1
Application #
7870810
Study Section
Special Emphasis Panel (ZDK1-GRB-6 (O1))
Project Start
2009-09-01
Project End
2014-08-31
Budget Start
2009-09-01
Budget End
2010-07-31
Support Year
1
Fiscal Year
2009
Total Cost
$2
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Na, Rong; Helfand, Brian T; Chen, Haitao et al. (2017) A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Prostate 77:1213-1220
Kulac, Ibrahim; Gumuskaya, Berrak; Drake, Charles G et al. (2016) Peripheral Zone Inflammation Is Not Strongly Associated With Lower Urinary Tract Symptom Incidence and Progression in the Placebo Arm of the Prostate Cancer Prevention Trial?. Prostate 76:1399-408
Torkko, Kathleen C; Wilson, R Storey; Smith, Elizabeth E et al. (2015) Prostate Biopsy Markers of Inflammation are Associated with Risk of Clinical Progression of Benign Prostatic Hyperplasia: Findings from the MTOPS Study. J Urol 194:454-61
Mondul, Alison M; Giovannucci, Edward; Platz, Elizabeth A (2014) A prospective study of obesity, and the incidence and progression of lower urinary tract symptoms. J Urol 191:715-21
Mondul, Alison M; Giovannucci, Edward; Platz, Elizabeth A (2013) A prospective study of statin drug use and lower urinary tract symptoms in older men. Am J Epidemiol 178:797-803
Platz, Elizabeth A; Joshu, Corinne E; Mondul, Alison M et al. (2012) Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol 188:496-501
Mooney, Steven M; Rajagopalan, Krithika; Williams, Brenten H et al. (2011) Creatine kinase brain overexpression protects colorectal cells from various metabolic and non-metabolic stresses. J Cell Biochem 112:1066-75
Rajagopalan, Krithika; Mooney, Steven M; Parekh, Nehal et al. (2011) A majority of the cancer/testis antigens are intrinsically disordered proteins. J Cell Biochem 112:3256-67
Zeng, Yu; He, Yanan; Yang, Fan et al. (2011) The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein. J Biol Chem 286:13985-94